ClinicalTrials.gg
CompletedNCT01541215Ellipse™Updated Jul 2, 2021Results posted

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

A Phase 3 interventional study of liraglutide and placebo in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 185 sites in 36 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-07-02.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
135
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 151 studies testing liraglutide in Diabetes Mellitus, Type 2 — 6 open to participants now, 7 under way, 1 of them phase 3. Liraglutide · Diabetes Mellitus, Type 2.

Enrollment
55th of 151
135 · median 62
Started
2012
with 20 others
Phase 3
45 of 151
1 open now
Registered
56th of 151
by date
Lead sponsor
63 of 151
Novo Nordisk A/S

Among the 151 studies testing liraglutide in Diabetes Mellitus, Type 2, this one is the 55th largest by enrollment, is one of 21 that started in 2012, is one of 45 in phase 3, and was the 56th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 151 studies testing liraglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About liraglutide

Liraglutide: first FDA approval 2010 (VICTOZA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies testing liraglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted globally. The aim of this trial is to assess the efficacy and safety of liraglutide in the paediatric population in order to potentially address the unmet need for treatment of children and adolescents with type 2 diabetes.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

This study's enrollment of 135 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: - Children and adolescents between the ages of 10-16 years. Subjects cannot turn 17 years and 11 months before the end of treatment (52 weeks) - Diagnosis of type 2 diabetes mellitus and treated for at least 30 days with: diet and exercise alone, diet and exercise in combination with metformin monotherapy, diet and exercise in combination with metformin and a stable (Stable is defined as basal insulin adjustments up to 15%) dose of basal insulin, diet and exercise in combination with a stable (Stable is defined as basal insulin adjustments up to 15%) dose of basal insulin - : 7.0-11% (inclusive) if diet and exercise treated or 6.5-11% (inclusive) if treated with metformin as monotherapy, basal insulin as monotherapy or metformin and basal insulin in combination - (BMI) above 85% percentile of the general age and gender matched population Exclusion Criteria: - Type 1 diabetes - Maturity onset diabetes of the young (MODY) - Use of any antidiabetic agent other than metformin and/or basal insulin within 90 days prior to screening - Recurrent severe hypoglycaemia or hypoglycaemic unawareness as judged by the investigator - History of chronic pancreatitis or idiopathic acute pancreatitis - Any disorder, except for conditions associated with type 2 diabetes history which in the investigator's opinion could interfere with results of the trial - Uncontrolled hypertension, treated or untreated above 99th percentile for age and gender in children - Known or suspected abuse of alcohol or drugs/narcotics

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
135 participants (actual)

Study arms

  • Experimental
    Lira + Met

    Drug: liraglutide · Drug: metformin

  • Placebo comparator
    Placebo + Met

    Drug: placebo · Drug: metformin

Interventions

  • Administered subcutaneously (s.c., under the skin) once daily.1.8 mg or maximum tolerated dose (MTD: 0.6 mg, 1.2 mg, 1.8 mg) for 26 weeks. Subjects will continue treatment in a 26 week open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.

  • Drugplacebo

    Administered subcutaneously (s.c., under the skin) once daily for 26 weeks. Subjects will discontinue placebo treatment in the open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.

  • Tablets administered for 26 weeks. Maximum tolerated dose (MTD) between 1000-2000 mg at the discretion of the investigator. Subjects will continue treatment in a 26 week open-labelled extension.

07

What researchers measure

Primary outcomes

  1. Change in HbA1c (Glycosylated Haemoglobin)

    Change in HbA1c from baseline to week 26. All available data were used for the primary analysis, including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 26

Secondary outcomes

  1. Change From Baseline in Fasting Plasma Glucose (FPG)

    Change in FPG from baseline to week 26. All available data were used for the analysis, including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 26

  2. Number of Subjects Having HbA1c Below 7.0%

    Percentage of subjects having HbA1c \<7.0%. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 26

  3. Change From Baseline in Body Mass Index (BMI) Standard Deviation Score (SDS)

    Change in BMI SDS from baseline to week 26. BMI SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' BMI provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the world health organisation (WHO) Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 26

  4. Number of Subjects Having HbA1c Below 7.0%

    Number of subjects achieving HbA1c \<7.0% after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 52

  5. Number of Subjects Having HbA1c Maximum 6.5%

    Number of subjects achieving HbA1c \<=6.5% after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 26

  6. Number of Subjects Having HbA1c Maximum 6.5%

    Number of subjects achieving HbA1c \<=6.5% after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 52

  7. Number of Subjects Having HbA1c Below 7.0% Without Severe or Minor Hypoglycaemic Episodes

    Number of subjects achieving HbA1c \<7.0% without severe or minor hypoglycaemic episodes after 26 weeks. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemia was defined as meeting either of the below criteria: 1. an episode with symptoms consistent with hypoglycaemia with confirmation by blood glucose \<2.8 mmol/L (50 mg/dL) or plasma glucose \<3.1 mmol/L (56 mg/dL), and which was handled by the subject him/herself 2. any asymptomatic blood glucose value \<2.8 mmol/L (50 mg/dL) or plasma glucose value \<3.1 mmol/L (56 mg/dL) All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 26

  8. Number of Subjects Having HbA1c Below 7.0% Without Severe or Minor Hypoglycaemic Episodes

    Number of subjects achieving HbA1c \<7.0% without severe or minor hypoglycaemic episodes after 52 weeks. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemia was defined as meeting either of the below criteria: 1. an episode with symptoms consistent with hypoglycaemia with confirmation by blood glucose \<2.8 mmol/L (50 mg/dL) or plasma glucose \<3.1 mmol/L (56 mg/dL), and which was handled by the subject him/herself 2. any asymptomatic blood glucose value \<2.8 mmol/L (50 mg/dL) or plasma glucose value \<3.1 mmol/L (56 mg/dL) All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 52

  9. Number of Subjects Having HbA1c Below 7.5%

    Number of subjects achieving HbA1c \<7.5% after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 26

  10. Number of Subjects Having HbA1c Below 7.5%

    Number of subjects achieving HbA1c \<7.5% after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 52

  11. Change in HbA1c

    Change in HbA1c from baseline to week 52. All available data were used for the analysis, including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 52

  12. Change in FPG

    Change in FPG from baseline to week 52. All available data were used for the analysis, including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 52

  13. Change in Mean 7-point Self-measured Plasma Glucose

    Change in mean 7-point self-measured plasma glucose after 26 weeks. Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner and at bedtime. Mean 7-point SMPG was defined as the area under the profile (calculated using the trapezoidal method) divided by time. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 26

  14. Change From Baseline in 7-point Self-measured Plasma Glucose

    Change in mean 7-point self-measured plasma glucose after 52 weeks. Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner and at bedtime. Mean 7-point SMPG was defined as the area under the profile (calculated using the trapezoidal method) divided by time. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 52

  15. Change in Post-prandial Increments (From Before Meal to 90 Min After Breakfast, Lunch, and Dinner)

    Change in post-prandial increments (from before meal to 90 min after breakfast, lunch, and dinner) after 26 weeks. Post-prandial increment for each meal (breakfast, lunch, and dinner) was derived from the 7-point SMPG profile as the difference between post-prandial plasma glucose values and the plasma glucose values before the meal. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 26

  16. Change in Post-prandial Increments (From Before Meal to 90 Min After Breakfast, Lunch, and Dinner)

    Change in post-prandial increments (from before meal to 90 min after breakfast, lunch, and dinner) after 52 weeks. Post-prandial increment for each meal (breakfast, lunch, and dinner) was derived from the 7-point SMPG profile as the difference between post-prandial plasma glucose values and the plasma glucose values before the meal. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 52

  17. Change in Mean Post-prandial Increment Across All Three Meals (Breakfast, Lunch, and Dinner)

    Change in mean post-prandial increment across all three meals (breakfast, lunch, and dinner) after 26 weeks. Post-prandial increment for each meal (breakfast, lunch, and dinner) was derived from the 7-point SMPG profile as the difference between post-prandial plasma glucose values and the plasma glucose values before the meal. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 26

  18. Change in Mean Post-prandial Increment Across All Three Meals (Breakfast, Lunch, and Dinner)

    Change in mean post-prandial increment across all three meals (breakfast, lunch, and dinner) after 52 weeks. Post-prandial increment for each meal (breakfast, lunch, and dinner) was derived from the 7-point SMPG profile as the difference between post-prandial plasma glucose values and the plasma glucose values before the meal. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 52

  19. Change From Baseline in Body Weight

    Change from baseline in body weight after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 26

  20. Change From Baseline in Body Weight

    Change from baseline in body weight after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 52

  21. Change From Baseline in BMI Standard Deviation Score (SDS)

    Change in BMI SDS from baseline to week 52. BMI SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' BMI provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 52

  22. Change in Blood Pressure (Systolic and Diastolic Blood Pressure)

    Change in blood pressure (systolic and diastolic blood pressure) after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 26

  23. Change in Blood Pressure (Systolic and Diastolic Blood Pressure)

    Change in blood pressure (systolic and diastolic blood pressure) after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 52

  24. Ratio to Baseline: Fasting Insulin

    Ratio to baseline (fasting insulin) at week 26. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 26

  25. Ratio to Baseline: Fasting Insulin

    Ratio to baseline (fasting insulin) at week 52. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 52

  26. Ratio to Baseline: Fasting Pro-insulin

    Ratio to baseline (fasting pro-insulin) at week 26. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 26

  27. Ratio to Baseline: Fasting Pro-insulin

    Ratio to baseline (fasting pro-insulin) at week 52. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 52

  28. Ratio to Baseline: Pro-insulin/Insulin Ratio

    Ratio to baseline (Pro-insulin/insulin ratio) after week 26. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 26

  29. Ratio to Baseline: Pro-insulin/Insulin Ratio

    Ratio to baseline (Pro-insulin/insulin ratio) after week 52. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 52

  30. Ratio to Baseline: Fasting Glucagon

    Ratio to baseline (fasting glucagon) at week 26. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 26

  31. Ratio to Baseline: Fasting Glucagon

    Ratio to baseline (fasting glucagon) at week 52. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 52

  32. Ratio to Baseline: Fasting C-peptide

    Ratio to baseline (fasting C-peptide) at week 26. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 26

  33. Ratio to Baseline: Fasting C-peptide

    Ratio to baseline (fasting C-peptide) at week 52. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 52

  34. Ratio to Baseline: Homeostasis Model Assessment of Beta-cell Function (HOMA-B)

    Ratio to baseline (HOMA-B) after 26 weeks. HOMA-B is an index of beta-cell function and was calculated from fasting insulin. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 26

  35. Ratio to Baseline: HOMA-B

    Ratio to baseline (HOMA-B) after 52 weeks. HOMA-B is an index of beta-cell function and was calculated from fasting insulin. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 52

  36. Ratio to Baseline: Homeostasis Model Assessment as an Index of Insulin Resistance (HOMA-IR)

    Ratio to baseline (HOMA-IR) after 26 weeks. HOMA-IR is an index of insulin resistance and was calculated from fasting insulin. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 26

  37. Ratio to Baseline: HOMA-IR

    Ratio to baseline (HOMA-IR) after 52 weeks. HOMA-IR is an index of insulin resistance and was calculated from fasting insulin. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 52

  38. Ratio to Baseline: Total Cholesterol

    Ratio to baseline (total cholesterol) after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 26

  39. Ratio to Baseline: Total Cholesterol

    Ratio to baseline (total cholesterol) after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 52

  40. Ratio to Baseline: Low Density Lipoprotein (LDL) Cholesterol

    Ratio to baseline (LDL cholesterol) after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 26

  41. Ratio to Baseline: LDL Cholesterol

    Ratio to baseline (LDL cholesterol) after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 52

  42. Ratio to Baseline: Very Low-density Lipoprotein (VLDL) Cholesterol

    Ratio to baseline (VLDL cholesterol) after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 26

  43. Ratio to Baseline: VLDL Cholesterol

    Ratio to baseline (VLDL cholesterol) after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 52

  44. Ratio to Baseline: High-density Lipoprotein (HDL) Cholesterol

    Ratio to baseline (HDL cholesterol) after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 26

  45. Ratio to Baseline: HDL Cholesterol

    Ratio to baseline (HDL cholesterol) after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 52

  46. Ratio to Baseline: Triglycerides

    Ratio to baseline (triglycerides) after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 26

  47. Ratio to Baseline: Triglycerides

    Ratio to baseline (triglycerides) after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 52

  48. Ratio to Baseline: Free Fatty Acids

    Ratio to baseline (free fatty acids) after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 26

  49. Ratio to Baseline: Free Fatty Acids

    Ratio to baseline (free fatty acids) after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 52

  50. Change From Baseline in Pulse

    Change from baseline in pulse 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 26

  51. Change From Baseline in Pulse

    Change from baseline in pulse 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 52

  52. Change From Baseline in Height SDS

    Change in height SDS from baseline to week 26. Height SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 26

  53. Change From Baseline in Height SDS

    Change in height SDS from baseline to week 52. Height SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 52

  54. Change in Bone Age Assessment (X-ray of Left Hand and Wrist)

    Change in bone age from baseline to week 52. If the baseline (week 0) bone age assessment indicated that all epiphyses were fused, then the assessment was not repeated at week 52.

    Time frame: Week 0, week 52

  55. Pubertal Assessment/Progression (Tanner Staging)

    Pubertal development was assessed in 3 areas (breast, penis and pubic hair development) by the Tanner staging in accordance with stages I-V. The Tanner staging assessment was no longer required to be performed once a subject reached the Tanner stage V, as judged by the investigator. Reported results are number of participants at different Tanner stages at week 0, week 26 and week 52.

    Time frame: Week 0, week 26, week 52

  56. Growth (Height Velocity)

    Growth (i.e., height velocity) is the change in height per year and is measured in cm/year. The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by the time (in days) between those measurement time points and multiplied by 365 days.

    Time frame: Week 0, week 26

  57. Growth (Height Velocity)

    Growth (i.e., height velocity) is the change in height per year and is measured in cm/year. The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by the time (in days) between those measurement time points and multiplied by 365 days.

    Time frame: Week 0, week 52

  58. Height Velocity SDS

    Height velocity SDS scores at week 26. Height velocity is change in height per year. The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 26

  59. Height Velocity SDS

    Height velocity SDS scores at week 52. Height velocity is change in height per year. The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

    Time frame: Week 0, week 52

  60. Number of Hypoglycaemic Episodes

    Total number of hypoglycaemic episodes according to American Diabetes Association (ADA) classification from baseline (week 0) to week 26.

    Time frame: 0-26 weeks

  61. Number of Hypoglycaemic Episodes

    Total number of hypoglycaemic episodes according to American Diabetes Association (ADA) classification from baseline (week 0) to week 52.

    Time frame: 0-52 weeks

  62. Number of Adverse Events (Week 0-26)

    Total number of adverse events during 26 weeks.

    Time frame: 0-26 weeks

  63. Number of Adverse Events (Week 0-52)

    Total number of adverse events during entire treatment period.

    Time frame: 0-52 weeks

  64. Number of Serious Adverse Events (Week 0-26)

    Total number of serious adverse events during 26 weeks.

    Time frame: 0-26 weeks

  65. Number of Serious Adverse Events (Week 0-52)

    Total number of serious adverse events during entire treatment period.

    Time frame: 0-52 weeks

  66. Number of Adverse Events (Week 53-104)

    This outcome is applicable only for the Liraglutide 1.8 mg treatment arm. Number of adverse events reported during follow-up 1 (week 53 to 104).

    Time frame: Week 53-104

  67. Number of Serious Adverse Events (Week 53-104)

    This outcome is applicable only for the Liraglutide 1.8 mg treatment arm. Number of serious adverse events reported during follow up 1 (week 53 to 104).

    Time frame: Weeks 53-104

  68. Growth (Height Velocity)- Week 104

    Growth (i.e., height velocity) is the change in height per year and is measured in cm/year. The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by the time (in days) between those measurement time points and multiplied by 365 days. This outcome is applicable only for the Liraglutide 1.8 mg treatment arm.

    Time frame: Week 0, week 104

  69. Height Velocity SDS- Week 104

    The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. This outcome is applicable only for the Liraglutide 1.8 mg treatment arm.

    Time frame: Week 0, week 104

  70. Change From Week 52 in Height SDS- Week 104

    Change in height SDS from week 52 to week 104. Height SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication. This outcome is applicable only for the Liraglutide 1.8 mg treatment arm.

    Time frame: Week 52, week 104

  71. Change in Pubertal Assessment/Progression (Tanner Staging)- Week 104

    Pubertal development was assessed in 3 areas (breast, penis and pubic hair development) by the Tanner staging in accordance with stages I-V, where stage I represents "pre-adoloscent development" and stage V represents "pubertal development equivalent to that of an adult". The Tanner staging assessment was no longer required to be performed once a subject reached the Tanner stage V, as judged by the investigator. Reported results are number of subjects at different Tanner stages at week 52 and week 104. This outcome is applicable only for the Liraglutide 1.8 mg treatment arm.

    Time frame: Week 52, week 104

  72. Change From Week 52 in Bone Age Assessment (X-ray of Left Hand and Wrist)- Week 104

    Change in bone age from week 52 to week 104. This outcome is applicable only for the Liraglutide 1.8 mg treatment arm.

    Time frame: Week 52, week 104

  73. Number of Adverse Events (Week 53-156)

    This outcome measure is applicable only for the Liraglutide 1.8 mg treatment arm. Number of adverse events reported during the follow-up period (weeks 53 to 156).

    Time frame: Week 53-156

  74. Number of Serious Adverse Events (Week 53-156)

    This outcome measure is applicable only for the Liraglutide 1.8 mg treatment arm. Number of serious adverse events reported during the follow up period (week 53 to 156).

    Time frame: Weeks 53-156

  75. Growth (Height Velocity)- Week 156

    Growth (i.e., height velocity) is the change in height per year and is measured in cm/year. The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by the time (in days) between those measurement time points and multiplied by 365 days. This outcome measure is applicable only for the Liraglutide 1.8 mg treatment arm.

    Time frame: Week 0, week 156

  76. Height Velocity SDS- Week 156

    The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. This outcome measure is applicable only for the Liraglutide 1.8 mg treatment arm.

    Time frame: Week 0, week 156

  77. Change From Week 52 in Height SDS- Week 156

    Change in height SDS from week 52 to week 156. Height SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication. This outcome measure is applicable only for the Liraglutide 1.8 mg treatment arm.

    Time frame: Week 52, week 156

  78. Change in Pubertal Assessment/Progression (Tanner Staging)- Week 156

    Pubertal development was assessed in 3 areas (breast, penis and pubic hair development) by the Tanner staging in accordance with stages I-V, where stage I represents "pre-adoloscent development" and stage V represents "pubertal development equivalent to that of an adult". The Tanner staging assessment was no longer required to be performed once a subject reached the Tanner stage V, as judged by the investigator. Reported results are number of subjects at different Tanner stages at week 52 and week 156. This outcome measure is applicable only for the Liraglutide 1.8 mg treatment arm.

    Time frame: Week 52, week 156

  79. Change From Week 52 in Bone Age Assessment (X-ray of Left Hand and Wrist)- Week 156

    Change in bone age from week 52 to week 156. This outcome measure is applicable only for the Liraglutide 1.8 mg treatment arm.

    Time frame: Week 52, week 156

08

Results

Posted Dec 11, 2018

Participant flow

The trial was conducted at 84 sites in 25 countries.

Treatment Period (52 Weeks)
Participant flow — Treatment Period (52 Weeks)
MilestoneLiraglutide 1.8 mgPlacebo
Started6669
Exposed6668
Completed5653
Not completed1016
Withdrew: Withdrawal criteria68
Withdrew: Non-compliance44
Withdrew: Adverse event01
Withdrew: Unclassified03
Follow up 1 (Weeks 53-104)
Participant flow — Follow up 1 (Weeks 53-104)
MilestoneLiraglutide 1.8 mgPlacebo
Started520
Completed500
Not completed20
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject10
Follow up 2 (Weeks 105-156)
Participant flow — Follow up 2 (Weeks 105-156)
MilestoneLiraglutide 1.8 mgPlacebo
Started480
Completed480
Not completed00

Outcome measures

PrimaryChange in HbA1c (Glycosylated Haemoglobin)

Change in HbA1c from baseline to week 26. All available data were used for the primary analysis, including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 26
Reported as:
Least squares mean · Percentage of HbA1c
Change in HbA1c (Glycosylated Haemoglobin)
Percentage of HbA1cLiraglutide 1.8 mgPlacebo
Change in HbA1c (Glycosylated Haemoglobin)-0.643 ± 0.2150.415 ± 0.216
Statistical analysis
  • Liraglutide 1.8 mg vs Placebo · Pattern Mixture Model · p = <0.001 · Treatment difference: -1.058 · 95% CI -1.653 to -0.464
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG)

Change in FPG from baseline to week 26. All available data were used for the analysis, including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 26
Reported as:
Least squares mean · mmol/L
Change From Baseline in Fasting Plasma Glucose (FPG)
mmol/LLiraglutide 1.8 mgPlacebo
Change From Baseline in Fasting Plasma Glucose (FPG)-1.076 ± 0.4360.801 ± 0.449
Statistical analysis
  • Liraglutide 1.8 mg vs Placebo · Pattern Mixture Model · p = 0.002 · Treatment difference: -1.878 · 95% CI -3.093 to -0.662
SecondaryNumber of Subjects Having HbA1c Below 7.0%

Percentage of subjects having HbA1c \<7.0%. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 26
Reported as:
Number · Percentage of subjects
Number of Subjects Having HbA1c Below 7.0%
Percentage of subjectsLiraglutide 1.8 mgPlacebo
Number of Subjects Having HbA1c Below 7.0%63.736.5
Statistical analysis
  • Liraglutide 1.8 mg vs Placebo · logistic regression model · p = <0.001 · Treatment odds ratio: 5.353 · 95% CI 2.105 to 13.615
SecondaryChange From Baseline in Body Mass Index (BMI) Standard Deviation Score (SDS)

Change in BMI SDS from baseline to week 26. BMI SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' BMI provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the world health organisation (WHO) Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 26
Reported as:
Least squares mean · SDS score
Change From Baseline in Body Mass Index (BMI) Standard Deviation Score (SDS)
SDS scoreLiraglutide 1.8 mgPlacebo
Change From Baseline in Body Mass Index (BMI) Standard Deviation Score (SDS)-0.254 ± 0.039-0.208 ± 0.039
Statistical analysis
  • Liraglutide 1.8 mg vs Placebo · Pattern Mixture Model · p = 0.392 · Treatment difference: -0.047 · 95% CI -0.153 to 0.060
SecondaryNumber of Subjects Having HbA1c Below 7.0%

Number of subjects achieving HbA1c \<7.0% after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Number of Subjects Having HbA1c Below 7.0%
ParticipantsLiraglutide 1.8 mgPlacebo
Yes2716
No2936
SecondaryNumber of Subjects Having HbA1c Maximum 6.5%

Number of subjects achieving HbA1c \<=6.5% after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Number of Subjects Having HbA1c Maximum 6.5%
ParticipantsLiraglutide 1.8 mgPlacebo
Yes2819
No3139
SecondaryNumber of Subjects Having HbA1c Maximum 6.5%

Number of subjects achieving HbA1c \<=6.5% after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Number of Subjects Having HbA1c Maximum 6.5%
ParticipantsLiraglutide 1.8 mgPlacebo
Yes2513
No3139
SecondaryNumber of Subjects Having HbA1c Below 7.0% Without Severe or Minor Hypoglycaemic Episodes

Number of subjects achieving HbA1c \<7.0% without severe or minor hypoglycaemic episodes after 26 weeks. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemia was defined as meeting either of the below criteria: 1. an episode with symptoms consistent with hypoglycaemia with confirmation by blood glucose \<2.8 mmol/L (50 mg/dL) or plasma glucose \<3.1 mmol/L (56 mg/dL), and which was handled by the subject him/herself 2. any asymptomatic blood glucose value \<2.8 mmol/L (50 mg/dL) or plasma glucose value \<3.1 mmol/L (56 mg/dL) All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Number of Subjects Having HbA1c Below 7.0% Without Severe or Minor Hypoglycaemic Episodes
ParticipantsLiraglutide 1.8 mgPlacebo
Yes3121
No2837
SecondaryNumber of Subjects Having HbA1c Below 7.0% Without Severe or Minor Hypoglycaemic Episodes

Number of subjects achieving HbA1c \<7.0% without severe or minor hypoglycaemic episodes after 52 weeks. Severe hypoglycaemia: An episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemia was defined as meeting either of the below criteria: 1. an episode with symptoms consistent with hypoglycaemia with confirmation by blood glucose \<2.8 mmol/L (50 mg/dL) or plasma glucose \<3.1 mmol/L (56 mg/dL), and which was handled by the subject him/herself 2. any asymptomatic blood glucose value \<2.8 mmol/L (50 mg/dL) or plasma glucose value \<3.1 mmol/L (56 mg/dL) All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Number of Subjects Having HbA1c Below 7.0% Without Severe or Minor Hypoglycaemic Episodes
ParticipantsLiraglutide 1.8 mgPlacebo
Yes2216
No3436
SecondaryNumber of Subjects Having HbA1c Below 7.5%

Number of subjects achieving HbA1c \<7.5% after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Number of Subjects Having HbA1c Below 7.5%
ParticipantsLiraglutide 1.8 mgPlacebo
Yes4329
No1629
SecondaryNumber of Subjects Having HbA1c Below 7.5%

Number of subjects achieving HbA1c \<7.5% after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 52
Reported as:
Count of participants · Participants
Number of Subjects Having HbA1c Below 7.5%
ParticipantsLiraglutide 1.8 mgPlacebo
Yes3623
No2029
SecondaryChange in HbA1c

Change in HbA1c from baseline to week 52. All available data were used for the analysis, including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 52
Reported as:
Mean · percentage of HbA1c
Change in HbA1c
percentage of HbA1cLiraglutide 1.8 mgPlacebo
Change in HbA1c-0.732 ± 1.4230.677 ± 1.523
SecondaryChange in FPG

Change in FPG from baseline to week 52. All available data were used for the analysis, including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 52
Reported as:
Mean · mmol/L
Change in FPG
mmol/LLiraglutide 1.8 mgPlacebo
Change in FPG-1.627 ± 2.7170.983 ± 3.954
SecondaryChange in Mean 7-point Self-measured Plasma Glucose

Change in mean 7-point self-measured plasma glucose after 26 weeks. Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner and at bedtime. Mean 7-point SMPG was defined as the area under the profile (calculated using the trapezoidal method) divided by time. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change in Mean 7-point Self-measured Plasma Glucose
mmol/LLiraglutide 1.8 mgPlacebo
Change in Mean 7-point Self-measured Plasma Glucose-2.384 ± 2.6380.198 ± 2.056
SecondaryChange From Baseline in 7-point Self-measured Plasma Glucose

Change in mean 7-point self-measured plasma glucose after 52 weeks. Subjects were instructed to measure their plasma glucose at following timepoints: before breakfast, 90 minutes after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 minutes after start of dinner and at bedtime. Mean 7-point SMPG was defined as the area under the profile (calculated using the trapezoidal method) divided by time. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 52
Reported as:
Mean · mmol/L
Change From Baseline in 7-point Self-measured Plasma Glucose
mmol/LLiraglutide 1.8 mgPlacebo
Change From Baseline in 7-point Self-measured Plasma Glucose-2.309 ± 2.968-0.748 ± 1.944
SecondaryChange in Post-prandial Increments (From Before Meal to 90 Min After Breakfast, Lunch, and Dinner)

Change in post-prandial increments (from before meal to 90 min after breakfast, lunch, and dinner) after 26 weeks. Post-prandial increment for each meal (breakfast, lunch, and dinner) was derived from the 7-point SMPG profile as the difference between post-prandial plasma glucose values and the plasma glucose values before the meal. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change in Post-prandial Increments (From Before Meal to 90 Min After Breakfast, Lunch, and Dinner)
mmol/LLiraglutide 1.8 mgPlacebo
Breakfast-1.528 ± 3.168-0.319 ± 3.228
Lunch-0.358 ± 3.281-0.658 ± 3.421
Dinner0.397 ± 3.790-0.226 ± 2.806
SecondaryChange in Post-prandial Increments (From Before Meal to 90 Min After Breakfast, Lunch, and Dinner)

Change in post-prandial increments (from before meal to 90 min after breakfast, lunch, and dinner) after 52 weeks. Post-prandial increment for each meal (breakfast, lunch, and dinner) was derived from the 7-point SMPG profile as the difference between post-prandial plasma glucose values and the plasma glucose values before the meal. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 52
Reported as:
Mean · mmol/L
Change in Post-prandial Increments (From Before Meal to 90 Min After Breakfast, Lunch, and Dinner)
mmol/LLiraglutide 1.8 mgPlacebo
Breakfast-1.802 ± 3.3380.053 ± 2.124
Lunch-0.735 ± 3.809-1.219 ± 3.038
Dinner-0.028 ± 3.501-0.195 ± 2.803
SecondaryChange in Mean Post-prandial Increment Across All Three Meals (Breakfast, Lunch, and Dinner)

Change in mean post-prandial increment across all three meals (breakfast, lunch, and dinner) after 26 weeks. Post-prandial increment for each meal (breakfast, lunch, and dinner) was derived from the 7-point SMPG profile as the difference between post-prandial plasma glucose values and the plasma glucose values before the meal. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 26
Reported as:
Mean · mmol/L
Change in Mean Post-prandial Increment Across All Three Meals (Breakfast, Lunch, and Dinner)
mmol/LLiraglutide 1.8 mgPlacebo
Change in Mean Post-prandial Increment Across All Three Meals (Breakfast, Lunch, and Dinner)-0.428 ± 2.172-0.362 ± 1.733
SecondaryChange in Mean Post-prandial Increment Across All Three Meals (Breakfast, Lunch, and Dinner)

Change in mean post-prandial increment across all three meals (breakfast, lunch, and dinner) after 52 weeks. Post-prandial increment for each meal (breakfast, lunch, and dinner) was derived from the 7-point SMPG profile as the difference between post-prandial plasma glucose values and the plasma glucose values before the meal. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 52
Reported as:
Mean · mmol/L
Change in Mean Post-prandial Increment Across All Three Meals (Breakfast, Lunch, and Dinner)
mmol/LLiraglutide 1.8 mgPlacebo
Change in Mean Post-prandial Increment Across All Three Meals (Breakfast, Lunch, and Dinner)-0.747 ± 2.245-0.397 ± 1.594
SecondaryChange From Baseline in Body Weight

Change from baseline in body weight after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 26
Reported as:
Mean · kg
Change From Baseline in Body Weight
kgLiraglutide 1.8 mgPlacebo
Change From Baseline in Body Weight-2.48 ± 5.59-0.87 ± 3.84
SecondaryChange From Baseline in Body Weight

Change from baseline in body weight after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 52
Reported as:
Mean · kg
Change From Baseline in Body Weight
kgLiraglutide 1.8 mgPlacebo
Change From Baseline in Body Weight-2.27 ± 8.051.02 ± 4.64
SecondaryChange From Baseline in BMI Standard Deviation Score (SDS)

Change in BMI SDS from baseline to week 52. BMI SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' BMI provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 52
Reported as:
Mean · SDS score
Change From Baseline in BMI Standard Deviation Score (SDS)
SDS scoreLiraglutide 1.8 mgPlacebo
Change From Baseline in BMI Standard Deviation Score (SDS)-0.361 ± 0.542-0.166 ± 0.330
SecondaryChange in Blood Pressure (Systolic and Diastolic Blood Pressure)

Change in blood pressure (systolic and diastolic blood pressure) after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 26
Reported as:
Mean · mmHg
Change in Blood Pressure (Systolic and Diastolic Blood Pressure)
mmHgLiraglutide 1.8 mgPlacebo
Systolic Blood Pressure-1.65 ± 10.690.03 ± 10.05
Diastolic Blood Pressure-1.27 ± 8.390.97 ± 7.65
SecondaryChange in Blood Pressure (Systolic and Diastolic Blood Pressure)

Change in blood pressure (systolic and diastolic blood pressure) after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 52
Reported as:
Mean · mmHg
Change in Blood Pressure (Systolic and Diastolic Blood Pressure)
mmHgLiraglutide 1.8 mgPlacebo
Systolic Blood Pressure-0.77 ± 11.772.81 ± 8.48
Diastolic Blood Pressure0.46 ± 10.011.83 ± 7.26
SecondaryRatio to Baseline: Fasting Insulin

Ratio to baseline (fasting insulin) at week 26. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 26
Reported as:
Geometric mean · ratio
Ratio to Baseline: Fasting Insulin
ratioLiraglutide 1.8 mgPlacebo
Ratio to Baseline: Fasting Insulin0.9 ± 76.41.0 ± 77.9
SecondaryRatio to Baseline: Fasting Insulin

Ratio to baseline (fasting insulin) at week 52. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 52
Reported as:
Geometric mean · ratio
Ratio to Baseline: Fasting Insulin
ratioLiraglutide 1.8 mgPlacebo
Ratio to Baseline: Fasting Insulin1.0 ± 80.61.1 ± 142.8
SecondaryRatio to Baseline: Fasting Pro-insulin

Ratio to baseline (fasting pro-insulin) at week 26. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 26
Reported as:
Geometric mean · ratio
Ratio to Baseline: Fasting Pro-insulin
ratioLiraglutide 1.8 mgPlacebo
Ratio to Baseline: Fasting Pro-insulin0.62 ± 110.30.88 ± 131.6
SecondaryRatio to Baseline: Fasting Pro-insulin

Ratio to baseline (fasting pro-insulin) at week 52. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 52
Reported as:
Geometric mean · ratio
Ratio to Baseline: Fasting Pro-insulin
ratioLiraglutide 1.8 mgPlacebo
Ratio to Baseline: Fasting Pro-insulin0.62 ± 118.00.79 ± 121.0
SecondaryRatio to Baseline: Pro-insulin/Insulin Ratio

Ratio to baseline (Pro-insulin/insulin ratio) after week 26. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 26
Reported as:
Geometric mean · ratio
Ratio to Baseline: Pro-insulin/Insulin Ratio
ratioLiraglutide 1.8 mgPlacebo
Ratio to Baseline: Pro-insulin/Insulin Ratio0.690 ± 102.40.923 ± 197.6
SecondaryRatio to Baseline: Pro-insulin/Insulin Ratio

Ratio to baseline (Pro-insulin/insulin ratio) after week 52. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 52
Reported as:
Geometric mean · ratio
Ratio to Baseline: Pro-insulin/Insulin Ratio
ratioLiraglutide 1.8 mgPlacebo
Ratio to Baseline: Pro-insulin/Insulin Ratio0.689 ± 106.60.770 ± 225.1
SecondaryRatio to Baseline: Fasting Glucagon

Ratio to baseline (fasting glucagon) at week 26. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 26
Reported as:
Geometric mean · ratio
Ratio to Baseline: Fasting Glucagon
ratioLiraglutide 1.8 mgPlacebo
Ratio to Baseline: Fasting Glucagon0.98 ± 29.31.03 ± 32.4
SecondaryRatio to Baseline: Fasting Glucagon

Ratio to baseline (fasting glucagon) at week 52. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 52
Reported as:
Geometric mean · ratio
Ratio to Baseline: Fasting Glucagon
ratioLiraglutide 1.8 mgPlacebo
Ratio to Baseline: Fasting Glucagon1.01 ± 35.01.05 ± 32.7
SecondaryRatio to Baseline: Fasting C-peptide

Ratio to baseline (fasting C-peptide) at week 26. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 26
Reported as:
Geometric mean · ratio
Ratio to Baseline: Fasting C-peptide
ratioLiraglutide 1.8 mgPlacebo
Ratio to Baseline: Fasting C-peptide0.93 ± 39.70.84 ± 82.3
SecondaryRatio to Baseline: Fasting C-peptide

Ratio to baseline (fasting C-peptide) at week 52. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 52
Reported as:
Geometric mean · ratio
Ratio to Baseline: Fasting C-peptide
ratioLiraglutide 1.8 mgPlacebo
Ratio to Baseline: Fasting C-peptide0.94 ± 40.80.83 ± 56.5
SecondaryRatio to Baseline: Homeostasis Model Assessment of Beta-cell Function (HOMA-B)

Ratio to baseline (HOMA-B) after 26 weeks. HOMA-B is an index of beta-cell function and was calculated from fasting insulin. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 26
Reported as:
Geometric mean · ratio
Ratio to Baseline: Homeostasis Model Assessment of Beta-cell Function (HOMA-B)
ratioLiraglutide 1.8 mgPlacebo
Ratio to Baseline: Homeostasis Model Assessment of Beta-cell Function (HOMA-B)1.24 ± 96.91.01 ± 119.0
SecondaryRatio to Baseline: HOMA-B

Ratio to baseline (HOMA-B) after 52 weeks. HOMA-B is an index of beta-cell function and was calculated from fasting insulin. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 52
Reported as:
Geometric mean · ratio
Ratio to Baseline: HOMA-B
ratioLiraglutide 1.8 mgPlacebo
Ratio to Baseline: HOMA-B1.48 ± 105.00.93 ± 166.8
SecondaryRatio to Baseline: Homeostasis Model Assessment as an Index of Insulin Resistance (HOMA-IR)

Ratio to baseline (HOMA-IR) after 26 weeks. HOMA-IR is an index of insulin resistance and was calculated from fasting insulin. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 26
Reported as:
Geometric mean · ratio
Ratio to Baseline: Homeostasis Model Assessment as an Index of Insulin Resistance (HOMA-IR)
ratioLiraglutide 1.8 mgPlacebo
Ratio to Baseline: Homeostasis Model Assessment as an Index of Insulin Resistance (HOMA-IR)0.73 ± 80.50.98 ± 80.8
SecondaryRatio to Baseline: HOMA-IR

Ratio to baseline (HOMA-IR) after 52 weeks. HOMA-IR is an index of insulin resistance and was calculated from fasting insulin. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 52
Reported as:
Geometric mean · ratio
Ratio to Baseline: HOMA-IR
ratioLiraglutide 1.8 mgPlacebo
Ratio to Baseline: HOMA-IR0.82 ± 86.41.08 ± 140.3
SecondaryRatio to Baseline: Total Cholesterol

Ratio to baseline (total cholesterol) after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 26
Reported as:
Geometric mean · ratio
Ratio to Baseline: Total Cholesterol
ratioLiraglutide 1.8 mgPlacebo
Ratio to Baseline: Total Cholesterol0.975 ± 17.71.008 ± 13.3
SecondaryRatio to Baseline: Total Cholesterol

Ratio to baseline (total cholesterol) after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 52
Reported as:
Geometric mean · ratio
Ratio to Baseline: Total Cholesterol
ratioLiraglutide 1.8 mgPlacebo
Ratio to Baseline: Total Cholesterol1.013 ± 21.01.026 ± 13.5
SecondaryRatio to Baseline: Low Density Lipoprotein (LDL) Cholesterol

Ratio to baseline (LDL cholesterol) after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 26
Reported as:
Geometric mean · ratio
Ratio to Baseline: Low Density Lipoprotein (LDL) Cholesterol
ratioLiraglutide 1.8 mgPlacebo
Ratio to Baseline: Low Density Lipoprotein (LDL) Cholesterol0.998 ± 24.80.993 ± 20.4
SecondaryRatio to Baseline: LDL Cholesterol

Ratio to baseline (LDL cholesterol) after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 52
Reported as:
Geometric mean · ratio
Ratio to Baseline: LDL Cholesterol
ratioLiraglutide 1.8 mgPlacebo
Ratio to Baseline: LDL Cholesterol1.042 ± 46.31.035 ± 21.5
SecondaryRatio to Baseline: Very Low-density Lipoprotein (VLDL) Cholesterol

Ratio to baseline (VLDL cholesterol) after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 26
Reported as:
Geometric mean · ratio
Ratio to Baseline: Very Low-density Lipoprotein (VLDL) Cholesterol
ratioLiraglutide 1.8 mgPlacebo
Ratio to Baseline: Very Low-density Lipoprotein (VLDL) Cholesterol0.890 ± 51.61.035 ± 35.3
SecondaryRatio to Baseline: VLDL Cholesterol

Ratio to baseline (VLDL cholesterol) after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 52
Reported as:
Geometric mean · ratio
Ratio to Baseline: VLDL Cholesterol
ratioLiraglutide 1.8 mgPlacebo
Ratio to Baseline: VLDL Cholesterol0.983 ± 48.41.003 ± 45.5
SecondaryRatio to Baseline: High-density Lipoprotein (HDL) Cholesterol

Ratio to baseline (HDL cholesterol) after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 26
Reported as:
Geometric mean · ratio
Ratio to Baseline: High-density Lipoprotein (HDL) Cholesterol
ratioLiraglutide 1.8 mgPlacebo
Ratio to Baseline: High-density Lipoprotein (HDL) Cholesterol0.997 ± 18.70.981 ± 16.3
SecondaryRatio to Baseline: HDL Cholesterol

Ratio to baseline (HDL cholesterol) after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 52
Reported as:
Geometric mean · ratio
Ratio to Baseline: HDL Cholesterol
ratioLiraglutide 1.8 mgPlacebo
Ratio to Baseline: HDL Cholesterol1.028 ± 16.01.000 ± 18.8
SecondaryRatio to Baseline: Triglycerides

Ratio to baseline (triglycerides) after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 26
Reported as:
Geometric mean · ratio
Ratio to Baseline: Triglycerides
ratioLiraglutide 1.8 mgPlacebo
Ratio to Baseline: Triglycerides0.894 ± 50.61.038 ± 36.0
SecondaryRatio to Baseline: Triglycerides

Ratio to baseline (triglycerides) after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 52
Reported as:
Geometric mean · ratio
Ratio to Baseline: Triglycerides
ratioLiraglutide 1.8 mgPlacebo
Ratio to Baseline: Triglycerides0.964 ± 50.51.036 ± 48.4
SecondaryRatio to Baseline: Free Fatty Acids

Ratio to baseline (free fatty acids) after 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 26
Reported as:
Geometric mean · ratio
Ratio to Baseline: Free Fatty Acids
ratioLiraglutide 1.8 mgPlacebo
Ratio to Baseline: Free Fatty Acids1.023 ± 67.40.985 ± 47.5
SecondaryRatio to Baseline: Free Fatty Acids

Ratio to baseline (free fatty acids) after 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 52
Reported as:
Geometric mean · ratio
Ratio to Baseline: Free Fatty Acids
ratioLiraglutide 1.8 mgPlacebo
Ratio to Baseline: Free Fatty Acids0.928 ± 58.20.868 ± 54.8
SecondaryChange From Baseline in Pulse

Change from baseline in pulse 26 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 26
Reported as:
Mean · beats/minute
Change From Baseline in Pulse
beats/minuteLiraglutide 1.8 mgPlacebo
Change From Baseline in Pulse1.40 ± 10.890.33 ± 7.69
SecondaryChange From Baseline in Pulse

Change from baseline in pulse 52 weeks. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 52
Reported as:
Mean · beats/minute
Change From Baseline in Pulse
beats/minuteLiraglutide 1.8 mgPlacebo
Change From Baseline in Pulse-0.05 ± 10.39-0.28 ± 7.88
SecondaryChange From Baseline in Height SDS

Change in height SDS from baseline to week 26. Height SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 26
Reported as:
Mean · SDS score
Change From Baseline in Height SDS
SDS scoreLiraglutide 1.8 mgPlacebo
Change From Baseline in Height SDS-0.100 ± 0.133-0.042 ± 0.210
SecondaryChange From Baseline in Height SDS

Change in height SDS from baseline to week 52. Height SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 52
Reported as:
Mean · SDS score
Change From Baseline in Height SDS
SDS scoreLiraglutide 1.8 mgPlacebo
Change From Baseline in Height SDS-0.192 ± 0.223-0.134 ± 0.293
SecondaryChange in Bone Age Assessment (X-ray of Left Hand and Wrist)

Change in bone age from baseline to week 52. If the baseline (week 0) bone age assessment indicated that all epiphyses were fused, then the assessment was not repeated at week 52.

Time frame:
Week 0, week 52
Reported as:
Mean · years
Change in Bone Age Assessment (X-ray of Left Hand and Wrist)
yearsLiraglutide 1.8 mgPlacebo
Change in Bone Age Assessment (X-ray of Left Hand and Wrist)1.197 ± 0.8991.088 ± 0.889
SecondaryPubertal Assessment/Progression (Tanner Staging)

Pubertal development was assessed in 3 areas (breast, penis and pubic hair development) by the Tanner staging in accordance with stages I-V. The Tanner staging assessment was no longer required to be performed once a subject reached the Tanner stage V, as judged by the investigator. Reported results are number of participants at different Tanner stages at week 0, week 26 and week 52.

Time frame:
Week 0, week 26, week 52
Reported as:
Count of participants · Participants
Pubertal Assessment/Progression (Tanner Staging)
ParticipantsLiraglutide 1.8 mgPlacebo
Female - Breast development - Week 0 — Stage I10
Female - Breast development - Week 0 — Stage II20
Female - Breast development - Week 0 — Stage III410
Female - Breast development - Week 0 — Stage IV89
Female - Breast development - Week 0 — Stage V2623
Female - Breast development - Week 26 — Stage I00
Female - Breast development - Week 26 — Stage II10
Female - Breast development - Week 26 — Stage III24
Female - Breast development - Week 26 — Stage IV510
Female - Breast development - Week 26 — Stage V2922
Female - Breast development - Week 52 — Stage I00
Female - Breast development - Week 52 — Stage II00
Female - Breast development - Week 52 — Stage III12
Female - Breast development - Week 52 — Stage IV59
Female - Breast development - Week 52 — Stage V2722
Male - Penis Development - Week 0 — Stage I20
Male - Penis Development - Week 0 — Stage II13
Male - Penis Development - Week 0 — Stage III26
Male - Penis Development - Week 0 — Stage IV911
Male - Penis Development - Week 0 — Stage V116
Male - Penis Development - Week 26 — Stage I20
Male - Penis Development - Week 26 — Stage II11
Male - Penis Development - Week 26 — Stage III24
Male - Penis Development - Week 26 — Stage IV78
Male - Penis Development - Week 26 — Stage V1310
Male - Penis Development - Week 52 — Stage I10
Male - Penis Development - Week 52 — Stage II20
Male - Penis Development - Week 52 — Stage III02
Male - Penis Development - Week 52 — Stage IV76
Male - Penis Development - Week 52 — Stage V1513
Pubic Hair Development - Week 0 — Stage I33
Pubic Hair Development - Week 0 — Stage II30
Pubic Hair Development - Week 0 — Stage III810
Pubic Hair Development - Week 0 — Stage IV1425
Pubic Hair Development - Week 0 — Stage V3829
Pubic Hair Development - Week 26 — Stage I30
Pubic Hair Development - Week 26 — Stage II02
Pubic Hair Development - Week 26 — Stage III54
Pubic Hair Development - Week 26 — Stage IV1118
Pubic Hair Development - Week 26 — Stage V4334
Pubic Hair Development - Week 52 — Stage I10
Pubic Hair Development - Week 52 — Stage II10
Pubic Hair Development - Week 52 — Stage III42
Pubic Hair Development - Week 52 — Stage IV817
Pubic Hair Development - Week 52 — Stage V4334
SecondaryGrowth (Height Velocity)

Growth (i.e., height velocity) is the change in height per year and is measured in cm/year. The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by the time (in days) between those measurement time points and multiplied by 365 days.

Time frame:
Week 0, week 26
Reported as:
Mean · cm/year
Growth (Height Velocity)
cm/yearLiraglutide 1.8 mgPlacebo
Growth (Height Velocity)1.633 ± 2.0162.486 ± 2.834
SecondaryGrowth (Height Velocity)

Growth (i.e., height velocity) is the change in height per year and is measured in cm/year. The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by the time (in days) between those measurement time points and multiplied by 365 days.

Time frame:
Week 0, week 52
Reported as:
Mean · cm/year
Growth (Height Velocity)
cm/yearLiraglutide 1.8 mgPlacebo
Growth (Height Velocity)1.345 ± 1.7301.817 ± 2.043
SecondaryHeight Velocity SDS

Height velocity SDS scores at week 26. Height velocity is change in height per year. The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 26
Reported as:
Mean · SDS score
Height Velocity SDS
SDS scoreLiraglutide 1.8 mgPlacebo
Height Velocity SDS-1.24 ± 1.695-0.557 ± 2.058
SecondaryHeight Velocity SDS

Height velocity SDS scores at week 52. Height velocity is change in height per year. The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication.

Time frame:
Week 0, week 52
Reported as:
Mean · SDS score
Height Velocity SDS
SDS scoreLiraglutide 1.8 mgPlacebo
Height Velocity SDS-0.887 ± 1.460-0.551 ± 1.711
SecondaryNumber of Hypoglycaemic Episodes

Total number of hypoglycaemic episodes according to American Diabetes Association (ADA) classification from baseline (week 0) to week 26.

Time frame:
0-26 weeks
Reported as:
Number · hypoglycaemic episodes
Number of Hypoglycaemic Episodes
hypoglycaemic episodesLiraglutide 1.8 mgPlacebo
Number of Hypoglycaemic Episodes9243
SecondaryNumber of Hypoglycaemic Episodes

Total number of hypoglycaemic episodes according to American Diabetes Association (ADA) classification from baseline (week 0) to week 52.

Time frame:
0-52 weeks
Reported as:
Number · hypoglycaemic episodes
Number of Hypoglycaemic Episodes
hypoglycaemic episodesLiraglutide 1.8 mgPlacebo
Number of Hypoglycaemic Episodes16063
SecondaryNumber of Adverse Events (Week 0-26)

Total number of adverse events during 26 weeks.

Time frame:
0-26 weeks
Reported as:
Number · events
Number of Adverse Events (Week 0-26)
eventsLiraglutide 1.8 mgPlacebo
Number of Adverse Events (Week 0-26)310230
SecondaryNumber of Adverse Events (Week 0-52)

Total number of adverse events during entire treatment period.

Time frame:
0-52 weeks
Reported as:
Number · events
Number of Adverse Events (Week 0-52)
eventsLiraglutide 1.8 mgPlacebo
Number of Adverse Events (Week 0-52)426321
SecondaryNumber of Serious Adverse Events (Week 0-26)

Total number of serious adverse events during 26 weeks.

Time frame:
0-26 weeks
Reported as:
Number · events
Number of Serious Adverse Events (Week 0-26)
eventsLiraglutide 1.8 mgPlacebo
Number of Serious Adverse Events (Week 0-26)74
SecondaryNumber of Serious Adverse Events (Week 0-52)

Total number of serious adverse events during entire treatment period.

Time frame:
0-52 weeks
Reported as:
Number · events
Number of Serious Adverse Events (Week 0-52)
eventsLiraglutide 1.8 mgPlacebo
Number of Serious Adverse Events (Week 0-52)105
SecondaryNumber of Adverse Events (Week 53-104)

This outcome is applicable only for the Liraglutide 1.8 mg treatment arm. Number of adverse events reported during follow-up 1 (week 53 to 104).

Time frame:
Week 53-104
Reported as:
Number · events
Number of Adverse Events (Week 53-104)
eventsLiraglutide 1.8 mg: Follow-up 1
Number of Adverse Events (Week 53-104)30
SecondaryNumber of Serious Adverse Events (Week 53-104)

This outcome is applicable only for the Liraglutide 1.8 mg treatment arm. Number of serious adverse events reported during follow up 1 (week 53 to 104).

Time frame:
Weeks 53-104
Reported as:
Number · events
Number of Serious Adverse Events (Week 53-104)
eventsLiraglutide 1.8 mg: Follow-up 1
Number of Serious Adverse Events (Week 53-104)7
SecondaryGrowth (Height Velocity)- Week 104

Growth (i.e., height velocity) is the change in height per year and is measured in cm/year. The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by the time (in days) between those measurement time points and multiplied by 365 days. This outcome is applicable only for the Liraglutide 1.8 mg treatment arm.

Time frame:
Week 0, week 104
Reported as:
Mean · cm/year
Growth (Height Velocity)- Week 104
cm/yearLiraglutide 1.8 mg: Follow-up 1
Growth (Height Velocity)- Week 1041.149 ± 1.776
SecondaryHeight Velocity SDS- Week 104

The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. This outcome is applicable only for the Liraglutide 1.8 mg treatment arm.

Time frame:
Week 0, week 104
Reported as:
Mean · SDS score
Height Velocity SDS- Week 104
SDS scoreLiraglutide 1.8 mg: Follow-up 1
Height Velocity SDS- Week 104-0.523 ± 1.466
SecondaryChange From Week 52 in Height SDS- Week 104

Change in height SDS from week 52 to week 104. Height SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication. This outcome is applicable only for the Liraglutide 1.8 mg treatment arm.

Time frame:
Week 52, week 104
Reported as:
Mean · SDS score
Change From Week 52 in Height SDS- Week 104
SDS scoreLiraglutide 1.8 mg: Follow-up 1
Change From Week 52 in Height SDS- Week 104-0.133 ± 0.338
SecondaryChange in Pubertal Assessment/Progression (Tanner Staging)- Week 104

Pubertal development was assessed in 3 areas (breast, penis and pubic hair development) by the Tanner staging in accordance with stages I-V, where stage I represents "pre-adoloscent development" and stage V represents "pubertal development equivalent to that of an adult". The Tanner staging assessment was no longer required to be performed once a subject reached the Tanner stage V, as judged by the investigator. Reported results are number of subjects at different Tanner stages at week 52 and week 104. This outcome is applicable only for the Liraglutide 1.8 mg treatment arm.

Time frame:
Week 52, week 104
Reported as:
Count of participants · Participants
Change in Pubertal Assessment/Progression (Tanner Staging)- Week 104
ParticipantsLiraglutide 1.8 mg: Follow-up 1
Female- Breast development- Week 52 — Stage I0
Female- Breast development- Week 52 — Stage II0
Female- Breast development- Week 52 — Stage III1
Female- Breast development- Week 52 — Stage IV5
Female- Breast development- Week 52 — Stage V21
Female- Breast development- Week 104 — Stage I0
Female- Breast development- Week 104 — Stage II0
Female- Breast development- Week 104 — Stage III0
Female- Breast development- Week 104 — Stage IV5
Female- Breast development- Week 104 — Stage V11
Male- Penis development- Week 52 — Stage I1
Male- Penis development- Week 52 — Stage II2
Male- Penis development- Week 52 — Stage III0
Male- Penis development- Week 52 — Stage IV7
Male- Penis development- Week 52 — Stage V14
Male- Penis development- Week 104 — Stage I0
Male- Penis development- Week 104 — Stage II1
Male- Penis development- Week 104 — Stage III0
Male- Penis development- Week 104 — Stage IV5
Male- Penis development- Week 104 — Stage V8
Female- Pubic hair development- Week 52 — Stage I0
Female- Pubic hair development- Week 52 — Stage II0
Female- Pubic hair development- Week 52 — Stage III2
Female- Pubic hair development- Week 52 — Stage IV2
Female- Pubic hair development- Week 52 — Stage V22
Female- Pubic hair development- Week 104 — Stage I0
Female- Pubic hair development- Week 104 — Stage II0
Female- Pubic hair development- Week 104 — Stage III1
Female- Pubic hair development- Week 104 — Stage IV2
Female- Pubic hair development- Week 104 — Stage V13
Male- Pubic hair development- Week 52 — Stage I1
Male- Pubic hair development- Week 52 — Stage II1
Male- Pubic hair development- Week 52 — Stage III2
Male- Pubic hair development- Week 52 — Stage IV6
Male- Pubic hair development- Week 52 — Stage V14
Male- Pubic hair development- Week 104 — Stage I0
Male- Pubic hair development- Week 104 — Stage II1
Male- Pubic hair development- Week 104 — Stage III0
Male- Pubic hair development- Week 104 — Stage IV4
Male- Pubic hair development- Week 104 — Stage V9
SecondaryChange From Week 52 in Bone Age Assessment (X-ray of Left Hand and Wrist)- Week 104

Change in bone age from week 52 to week 104. This outcome is applicable only for the Liraglutide 1.8 mg treatment arm.

Time frame:
Week 52, week 104
Reported as:
Mean · Years
Change From Week 52 in Bone Age Assessment (X-ray of Left Hand and Wrist)- Week 104
YearsLiraglutide 1.8 mg: Follow-up 1
Change From Week 52 in Bone Age Assessment (X-ray of Left Hand and Wrist)- Week 1041.231 ± 0.992
SecondaryNumber of Adverse Events (Week 53-156)

This outcome measure is applicable only for the Liraglutide 1.8 mg treatment arm. Number of adverse events reported during the follow-up period (weeks 53 to 156).

Time frame:
Week 53-156
Reported as:
Number · events
Number of Adverse Events (Week 53-156)
eventsLiraglutide 1.8 mg: Follow-up 1 and 2
Number of Adverse Events (Week 53-156)47
SecondaryNumber of Serious Adverse Events (Week 53-156)

This outcome measure is applicable only for the Liraglutide 1.8 mg treatment arm. Number of serious adverse events reported during the follow up period (week 53 to 156).

Time frame:
Weeks 53-156
Reported as:
Number · events
Number of Serious Adverse Events (Week 53-156)
eventsLiraglutide 1.8 mg: Follow-up 1 and 2
Number of Serious Adverse Events (Week 53-156)9
SecondaryGrowth (Height Velocity)- Week 156

Growth (i.e., height velocity) is the change in height per year and is measured in cm/year. The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by the time (in days) between those measurement time points and multiplied by 365 days. This outcome measure is applicable only for the Liraglutide 1.8 mg treatment arm.

Time frame:
Week 0, week 156
Reported as:
Mean · cm/year
Growth (Height Velocity)- Week 156
cm/yearLiraglutide 1.8 mg: Follow-up 1 and 2
Growth (Height Velocity)- Week 1561.100 ± 1.504
SecondaryHeight Velocity SDS- Week 156

The height velocity was calculated as the difference between current height and height at baseline (week 0) divided by time between those measurement time points and multiplied by 365 days. Height velocity SDS was calculated using following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. This outcome measure is applicable only for the Liraglutide 1.8 mg treatment arm.

Time frame:
Week 0, week 156
Reported as:
Mean · SDS score
Height Velocity SDS- Week 156
SDS scoreLiraglutide 1.8 mg: Follow-up 1 and 2
Height Velocity SDS- Week 1560.142 ± 1.156
SecondaryChange From Week 52 in Height SDS- Week 156

Change in height SDS from week 52 to week 156. Height SDS was calculated using the following formula: Z=\[(value /M)\^L - 1\] / S\*L; where L, M and S are median (M), skewness (L) and variation coefficient (S) of children/adolescents' height provided for each sex and age. For each subject, a standard deviation score Z (SDS) was calculated based on age and sex referring to the values L, M and S. The method is described in the WHO Multicentre Growth Reference, which also contains the values for L, M and S by age and sex. For Z (SDS) scores below -3 and above 3, the score was adjusted as described in the WHO instruction. All available data were used for the analysis including data collected after treatment discontinuation and initiation of rescue medication. This outcome measure is applicable only for the Liraglutide 1.8 mg treatment arm.

Time frame:
Week 52, week 156
Reported as:
Mean · SDS score
Change From Week 52 in Height SDS- Week 156
SDS scoreLiraglutide 1.8 mg: Follow-up 1 and 2
Change From Week 52 in Height SDS- Week 156-0.224 ± 0.446
SecondaryChange in Pubertal Assessment/Progression (Tanner Staging)- Week 156

Pubertal development was assessed in 3 areas (breast, penis and pubic hair development) by the Tanner staging in accordance with stages I-V, where stage I represents "pre-adoloscent development" and stage V represents "pubertal development equivalent to that of an adult". The Tanner staging assessment was no longer required to be performed once a subject reached the Tanner stage V, as judged by the investigator. Reported results are number of subjects at different Tanner stages at week 52 and week 156. This outcome measure is applicable only for the Liraglutide 1.8 mg treatment arm.

Time frame:
Week 52, week 156
Reported as:
Count of participants · Participants
Change in Pubertal Assessment/Progression (Tanner Staging)- Week 156
ParticipantsLiraglutide 1.8 mg: Follow-up 1 and 2
Female- Breast development- Week 52 — Stage I0
Female- Breast development- Week 52 — Stage II0
Female- Breast development- Week 52 — Stage III1
Female- Breast development- Week 52 — Stage IV5
Female- Breast development- Week 52 — Stage V21
Female- Breast development- Week 156 — Stage I0
Female- Breast development- Week 156 — Stage II0
Female- Breast development- Week 156 — Stage III0
Female- Breast development- Week 156 — Stage IV3
Female- Breast development- Week 156 — Stage V11
Male- Penis development- Week 52 — Stage I1
Male- Penis development- Week 52 — Stage II2
Male- Penis development- Week 52 — Stage III0
Male- Penis development- Week 52 — Stage IV7
Male- Penis development- Week 52 — Stage V14
Male- Penis development- Week 156 — Stage I0
Male- Penis development- Week 156 — Stage II0
Male- Penis development- Week 156 — Stage III1
Male- Penis development- Week 156 — Stage IV3
Male- Penis development- Week 156 — Stage V9
Female- Pubic hair development- Week 52 — Stage I0
Female- Pubic hair development- Week 52 — Stage II0
Female- Pubic hair development- Week 52 — Stage III2
Female- Pubic hair development- Week 52 — Stage IV2
Female- Pubic hair development- Week 52 — Stage V22
Female- Pubic hair development- Week 156 — Stage I0
Female- Pubic hair development- Week 156 — Stage II0
Female- Pubic hair development- Week 156 — Stage III0
Female- Pubic hair development- Week 156 — Stage IV2
Female- Pubic hair development- Week 156 — Stage V11
Male- Pubic hair development- Week 52 — Stage I1
Male- Pubic hair development- Week 52 — Stage II1
Male- Pubic hair development- Week 52 — Stage III2
Male- Pubic hair development- Week 52 — Stage IV6
Male- Pubic hair development- Week 52 — Stage V14
Male- Pubic hair development- Week 156 — Stage I0
Male- Pubic hair development- Week 156 — Stage II0
Male- Pubic hair development- Week 156 — Stage III1
Male- Pubic hair development- Week 156 — Stage IV3
Male- Pubic hair development- Week 156 — Stage V10
SecondaryChange From Week 52 in Bone Age Assessment (X-ray of Left Hand and Wrist)- Week 156

Change in bone age from week 52 to week 156. This outcome measure is applicable only for the Liraglutide 1.8 mg treatment arm.

Time frame:
Week 52, week 156
Reported as:
Mean · Years
Change From Week 52 in Bone Age Assessment (X-ray of Left Hand and Wrist)- Week 156
YearsLiraglutide 1.8 mg: Follow-up 1 and 2
Change From Week 52 in Bone Age Assessment (X-ray of Left Hand and Wrist)- Week 1561.778 ± 1.277

Adverse events

Collected over Week 0 - 156. All presented AEs are TEAEs. A TEAE was defined as an event that had onset date on or after the first day of exposure to trial product and no later than 7 days after the last day of trial product administration.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Liraglutide 1.8 mg0/66 (0%)9/66 (13.6%)45/66 (68.2%)
Placebo0/68 (0%)4/68 (5.9%)49/68 (72.1%)
Liraglutide 1.8 mg: Follow-up 10/52 (0%)7/52 (13.5%)7/52 (13.5%)
Liraglutide 1.8 mg: Follow-up 20/48 (0%)2/48 (4.2%)1/48 (2.1%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventLiraglutide 1.8 mgPlaceboLiraglutide 1.8 mg: Follow-up 1Liraglutide 1.8 mg: Follow-up 2
HyperglycaemiaMetabolism and nutrition disorders1/661/682/520/48
Abdominal painGastrointestinal disorders1/660/680/521/48
AppendicitisInfections and infestations0/660/680/521/48
MalocclusionGastrointestinal disorders0/660/680/521/48
ConstipationGastrointestinal disorders0/660/681/520/48
Depressive symptomPsychiatric disorders0/660/681/520/48
FasciotomySurgical and medical procedures0/660/681/520/48
Metabolic surgerySurgical and medical procedures0/660/681/520/48
Subcutaneous abscessInfections and infestations0/660/681/520/48
Abscess neckInfections and infestations1/660/680/520/48
Most frequent other events
Showing 10 of 23
Most frequent other events
EventLiraglutide 1.8 mgPlaceboLiraglutide 1.8 mg: Follow-up 1Liraglutide 1.8 mg: Follow-up 2
NauseaGastrointestinal disorders19/669/681/520/48
NasopharyngitisInfections and infestations11/6619/682/520/48
VomitingGastrointestinal disorders17/666/682/520/48
DiarrhoeaGastrointestinal disorders15/6611/680/520/48
HeadacheNervous system disorders14/6613/680/520/48
Abdominal painGastrointestinal disorders11/665/681/520/48
DizzinessNervous system disorders8/662/680/520/48
Abdominal pain upperGastrointestinal disorders2/668/680/520/48
GastroenteritisInfections and infestations7/662/680/520/48
Upper respiratory tract infectionInfections and infestations6/665/680/520/48

Baseline characteristics

Full analysis set (FAS) - included all randomised subjects receiving at least one dose of liraglutide/placebo

Age, Continuous
Age, Continuous(years)Liraglutide 1.8 mgPlaceboTotal
Mean14.57 ± 1.7314.57 ± 1.7314.57 ± 1.72
Sex: Female, Male
Sex: Female, Male(Participants)Liraglutide 1.8 mgPlaceboTotal
Female414283
Male252651
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Liraglutide 1.8 mgPlaceboTotal
Hispanic or Latino162339
Not Hispanic or Latino504595
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Liraglutide 1.8 mgPlaceboTotal
American Indian or Alaska Native213
Asian10818
Native Hawaiian or Other Pacific Islander000
Black or African American9716
White424587
More than one race000
Unknown or Not Reported3710
Glycosylated hemoglobin (HbA1c)
Glycosylated hemoglobin (HbA1c)(percentage of HbA1c)Liraglutide 1.8 mgPlaceboTotal
Mean7.87 ± 1.357.69 ± 1.347.78 ± 1.34
09

Study locations

185 sites
  • Novo Nordisk Investigational Site
    Birmingham, Alabama 35233, United States
  • Novo Nordisk Investigational Site
    Phoenix, Arizona 85053, United States
  • Novo Nordisk Investigational Site
    Tucson, Arizona 85724-0001, United States
  • Novo Nordisk Investigational Site
    Corona, California 92880, United States
  • Novo Nordisk Investigational Site
    Costa Mesa, California 92626, United States
  • Novo Nordisk Investigational Site
    Long Beach, California 90806, United States
  • Novo Nordisk Investigational Site
    Los Angeles, California 90027, United States
  • Novo Nordisk Investigational Site
    Los Angeles, California 90048-1869, United States
  • Novo Nordisk Investigational Site
    Moreno Valley, California 92555, United States
  • Novo Nordisk Investigational Site
    Palo Alto, California 94304-1503, United States
  • Novo Nordisk Investigational Site
    San Diego, California 92123, United States
  • Novo Nordisk Investigational Site
    Ventura, California 93003, United States
  • Novo Nordisk Investigational Site
    New Haven, Connecticut 06511, United States
  • Novo Nordisk Investigational Site
    Wilmington, Delaware 19803, United States
  • Novo Nordisk Investigational Site
    Washington, District of Columbia 20011, United States
  • Novo Nordisk Investigational Site
    Jacksonville, Florida 32256, United States
  • Novo Nordisk Investigational Site
    Melbourne, Florida 32901, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33126, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33144, United States
  • Novo Nordisk Investigational Site
    Miami, Florida 33155, United States
  • Novo Nordisk Investigational Site
    Saint Petersburg, Florida 33701, United States
  • Novo Nordisk Investigational Site
    Tallahassee, Florida 32308, United States
  • Novo Nordisk Investigational Site
    Tampa, Florida 33612, United States
  • Novo Nordisk Investigational Site
    Atlanta, Georgia 30318, United States
  • Novo Nordisk Investigational Site
    Atlanta, Georgia 30322, United States
  • Novo Nordisk Investigational Site
    Columbus, Georgia 31904, United States
  • Novo Nordisk Investigational Site
    Bloomington, Indiana 47401, United States
  • Novo Nordisk Investigational Site
    Iowa City, Iowa 52242, United States
  • Novo Nordisk Investigational Site
    Topeka, Kansas 66606, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40503, United States
  • Novo Nordisk Investigational Site
    Lexington, Kentucky 40536-0284, United States
  • Novo Nordisk Investigational Site
    Silver Spring, Maryland 20910, United States
  • Novo Nordisk Investigational Site
    Worcester, Massachusetts 01655, United States
  • Novo Nordisk Investigational Site
    Detroit, Michigan 48201, United States
  • Novo Nordisk Investigational Site
    Grand Rapids, Michigan 49503, United States
  • Novo Nordisk Investigational Site
    Saint Paul, Minnesota 55102, United States
  • Novo Nordisk Investigational Site
    Columbia, Missouri 65201, United States
  • Novo Nordisk Investigational Site
    Kansas City, Missouri 64111, United States
  • Novo Nordisk Investigational Site
    Saint Louis, Missouri 63104, United States
  • Novo Nordisk Investigational Site
    Las Vegas, Nevada 89128, United States
  • Novo Nordisk Investigational Site
    Hackensack, New Jersey 07601, United States
  • Novo Nordisk Investigational Site
    West Orange, New Jersey 07052, United States
  • Novo Nordisk Investigational Site
    Buffalo, New York 14203, United States
  • Novo Nordisk Investigational Site
    New York, New York 10003, United States
  • Novo Nordisk Investigational Site
    New York, New York 10016, United States
  • Novo Nordisk Investigational Site
    New York, New York 10029, United States
  • Novo Nordisk Investigational Site
    Sleepy Hollow, New York 10591, United States
  • Novo Nordisk Investigational Site
    Cincinnati, Ohio 45229, United States
  • Novo Nordisk Investigational Site
    Toledo, Ohio 43606, United States
  • Novo Nordisk Investigational Site
    Hershey, Pennsylvania 17033, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19134, United States
  • Novo Nordisk Investigational Site
    Pittsburgh, Pennsylvania 15224, United States
  • Novo Nordisk Investigational Site
    Greenville, South Carolina 29615, United States
  • Novo Nordisk Investigational Site
    Rapid City, South Dakota 57701, United States
  • Novo Nordisk Investigational Site
    Chattanooga, Tennessee 37403, United States
  • Novo Nordisk Investigational Site
    Memphis, Tennessee 38105, United States
  • Novo Nordisk Investigational Site
    Memphis, Tennessee 38119-3821, United States
  • Novo Nordisk Investigational Site
    Memphis, Tennessee 38119, United States
  • Novo Nordisk Investigational Site
    Nashville, Tennessee 37232, United States
  • Novo Nordisk Investigational Site
    Amarillo, Texas 79106, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75235, United States
  • Novo Nordisk Investigational Site
    Edinburg, Texas 78539, United States
  • Novo Nordisk Investigational Site
    Fort Worth, Texas 76104, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77054, United States
  • Novo Nordisk Investigational Site
    Houston, Texas 77061, United States
  • Novo Nordisk Investigational Site
    Kerrville, Texas 78028, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78233, United States
  • Novo Nordisk Investigational Site
    Charlottesville, Virginia 22908, United States
  • Novo Nordisk Investigational Site
    Norfolk, Virginia 23507, United States
  • Novo Nordisk Investigational Site
    Charleston, West Virginia 25302, United States
  • Novo Nordisk Investigational Site
    Ipswich, Queensland 4305, Australia
  • Novo Nordisk Investigational Site
    Graz, 8036, Austria
  • Novo Nordisk Investigational Site
    Innsbruck, 6020, Austria
  • Novo Nordisk Investigational Site
    Salzburg, 5020, Austria
  • Novo Nordisk Investigational Site
    Wels, 4600, Austria
  • Novo Nordisk Investigational Site
    Brussel, 1090, Belgium
  • Novo Nordisk Investigational Site
    Bruxelles, 1200, Belgium
  • Novo Nordisk Investigational Site
    Leuven, 3000, Belgium
  • Novo Nordisk Investigational Site
    Porto Alegre, Rio Grande Do Sul 91350-250, Brazil
  • Novo Nordisk Investigational Site
    Edmonton, Alberta T5X 3N5, Canada
  • Novo Nordisk Investigational Site
    Winnipeg, Manitoba R3E 3P4, Canada
  • Novo Nordisk Investigational Site
    Brampton, Ontario L6T 0G1, Canada
  • Novo Nordisk Investigational Site
    Westmount, Quebec H3Z 1E5, Canada
  • Novo Nordisk Investigational Site
    Rijeka, 51000, Croatia
  • Novo Nordisk Investigational Site
    Zagreb, 10 000, Croatia
  • Novo Nordisk Investigational Site
    Herlev, 2730, Denmark
  • Novo Nordisk Investigational Site
    Næstved, 4700, Denmark
  • Novo Nordisk Investigational Site
    Alexandria, 21131, Egypt
  • Novo Nordisk Investigational Site
    Cairo, 11562, Egypt
  • Novo Nordisk Investigational Site
    Cairo, 11628, Egypt
  • Novo Nordisk Investigational Site
    Mansoura, 35516, Egypt
  • Novo Nordisk Investigational Site
    Marseille, 13006, France
  • Novo Nordisk Investigational Site
    MONTPELLIER cedex 05, 34295, France
  • Novo Nordisk Investigational Site
    Ludwigshafen, 67059, Germany
  • Novo Nordisk Investigational Site
    Mayen, 56727, Germany
  • Novo Nordisk Investigational Site
    Athens, 151 23, Greece
  • Novo Nordisk Investigational Site
    Athens, GR-17562, Greece
  • Novo Nordisk Investigational Site
    Goudi/ Athens, GR-11527, Greece
  • Novo Nordisk Investigational Site
    Thessaloniki, GR-54643, Greece

Showing the first 100 of 185 sites across 36 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Tamborlane WV, Barrientos-Perez M, Fainberg U, Frimer-Larsen H, Hafez M, Hale PM, Jalaludin MY, Kovarenko M, Libman I, Lynch JL, Rao P, Shehadeh N, Turan S, Weghuber D, Barrett T; Ellipse Trial Investigators. Liraglutide in Children and Adolescents with Type 2 Diabetes. N Engl J Med. 2019 Aug 15;381(7):637-646. doi: 10.1056/NEJMoa1903822. Epub 2019 Apr 28. PubMed 31034184 ↗
  • Bensignor MO, Bomberg EM, Bramante CT, Divyalasya TVS, Hale PM, Ramesh CK, Rudser KD, Kelly AS. Effect of liraglutide treatment on body mass index and weight parameters in children and adolescents with type 2 diabetes: Post hoc analysis of the ellipse trial. Pediatr Obes. 2021 Aug;16(8):e12778. doi: 10.1111/ijpo.12778. Epub 2021 Feb 25. PubMed 33634589 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2012 to primary completion in Nov 2017, 60 months.

Results were first posted in Dec 2018, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 60 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2012
First posted
Feb 29, 2012
StartActual
Nov 13, 2012
Primary completionActual
Nov 15, 2017
CompletionActual
May 20, 2020
Results first posted
Dec 11, 2018
Last update
Jul 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01541215
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Feb 29, 2012
Start date
Nov 13, 2012
Primary completion
Nov 15, 2017
Completion
May 20, 2020
Results posted
Dec 11, 2018
Last update
Jul 2, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liraglutide

Start the discussion